Silence Therapeutics plc
SLNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeSilence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of. The $850.9M market capitalization puts SLN squarely in small-cap range for its industry. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.
Market Cap
$850.9M
Beta
1.44
P/E (TTM)
—
P/E (Fwd)
-17.90
EPS (TTM)
$-1.29
EPS (Fwd)
$-0.77
ROE
-90.4%
ROA
-29.6%
Cash
$72.1M
Total Debt
$112,000
Free CF
-$23.6M
52W Change
203.3%
Annual Financials
Cash vs Debt
Where SLN stands vs its 150-day and 200-day moving averages
As of the August 25, 2026 close, SLN finished 72.82% above its 150-day moving average ($7.69) and 81.06% above its 200-day moving average ($7.34). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SLN overbought or oversold?
At the August 25, 2026 close, SLN's RSI(14) was 62.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $72.1M in cash and $112K in debt, SLN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$23.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -90.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $21.7M to $559K.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing SLN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.